Cart
sales@molnova.com
ONO-8713
CAS No. 459411-08-6
ONO-8713( —— )
Catalog No. M35732 CAS No. 459411-08-6
ONO-8713 is a selective prostaglandin E receptor subtype EP1 antagonist used to study diseases of the biblical system and metabolism-related diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 922 | In Stock |
|
| 10MG | 1121 | In Stock |
|
| 25MG | 1501 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | 2325 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameONO-8713
-
NoteResearch use only, not for human use.
-
Brief DescriptionONO-8713 is a selective prostaglandin E receptor subtype EP1 antagonist used to study diseases of the biblical system and metabolism-related diseases.
-
DescriptionONO-8713 is a selective prostaglandin E receptor subtype EP1 antagonist.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetProstaglandin Receptor
-
RecptorProstaglandin Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number459411-08-6
-
Formula Weight523.52
-
Molecular FormulaC25H24F3NO6S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN(S(=O)(=O)C1=CC=CO1)(CC(C)C)C2=C(OCC3=CC=C(C=CC(O)=O)C=C3)C=C(C(F)(F)F)C=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Watanabe K, et al. Inhibitory effect of a prostaglandin E receptor subtype EP(1) selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice. Cancer Lett. 2000 Aug 1;156(1):57-61. ?
molnova catalog
related products
-
Bupivacaine hydrochl...
Bupivacaine hydrochloride binds to the intracellular portion of voltage-gated sodium channels and blocks sodium influx into nerve cells.
-
2-Acetylbenzoic acid
2-Acetylbenzoic acid is more potent than 2-propionyloxybenzoic acid in inhibiting platelet function and platelet prostaglandin (PG) synthesis although the potencies of these agents were comparable in inhibiting prostacyclin (PGI2) synthesis.
-
MF-766
MF-766 is a highly potent, selective and orally active EP4 antagonist with a Ki of 0.23 nM. It behaves as a full antagonist with an IC50 of 1.4 nM (shifted to 1.8 nM in the presence of 10% HS) in the functional assay. It can be used for cancer and inflammation diseases research.
